Jennison Associates LLC Buys 83,115 Shares of NewAmsterdam Pharma (NASDAQ:NAMS)

Jennison Associates LLC increased its stake in NewAmsterdam Pharma (NASDAQ:NAMS) by 8.9% in the 3rd quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 1,020,278 shares of the company’s stock after purchasing an additional 83,115 shares during the quarter. Jennison Associates LLC owned about 1.13% of NewAmsterdam Pharma worth $16,937,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Banque Cantonale Vaudoise purchased a new position in NewAmsterdam Pharma during the 2nd quarter valued at about $38,000. Rosalind Advisors Inc. bought a new position in shares of NewAmsterdam Pharma in the second quarter valued at approximately $194,000. Wolverine Asset Management LLC increased its holdings in NewAmsterdam Pharma by 117.7% during the 2nd quarter. Wolverine Asset Management LLC now owns 15,524 shares of the company’s stock worth $298,000 after acquiring an additional 8,394 shares during the period. Sei Investments Co. boosted its stake in NewAmsterdam Pharma by 49.1% during the second quarter. Sei Investments Co. now owns 24,561 shares of the company’s stock valued at $472,000 after buying an additional 8,087 shares during the period. Finally, Lisanti Capital Growth LLC purchased a new position in NewAmsterdam Pharma in the third quarter worth $700,000. 89.89% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

NAMS has been the subject of several recent analyst reports. Piper Sandler reaffirmed an “overweight” rating and set a $37.00 price objective on shares of NewAmsterdam Pharma in a research note on Monday, September 23rd. Royal Bank of Canada reaffirmed an “outperform” rating and set a $31.00 price target on shares of NewAmsterdam Pharma in a report on Thursday, September 5th. Finally, Needham & Company LLC reiterated a “buy” rating and set a $36.00 price objective on shares of NewAmsterdam Pharma in a research report on Thursday. Six research analysts have rated the stock with a buy rating, According to data from MarketBeat, the company has a consensus rating of “Buy” and a consensus target price of $33.80.

Insider Activity at NewAmsterdam Pharma

In other news, CAO Louise Frederika Kooij sold 45,000 shares of the business’s stock in a transaction dated Tuesday, October 1st. The stock was sold at an average price of $15.72, for a total value of $707,400.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, major shareholder Nap B.V. Forgrowth sold 8,530 shares of the firm’s stock in a transaction that occurred on Friday, November 15th. The stock was sold at an average price of $25.02, for a total transaction of $213,420.60. Following the transaction, the insider now owns 11,812,033 shares in the company, valued at approximately $295,537,065.66. This trade represents a 0.07 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 86,803 shares of company stock valued at $1,755,307. 19.50% of the stock is owned by insiders.

NewAmsterdam Pharma Price Performance

Shares of NewAmsterdam Pharma stock opened at $20.20 on Friday. NewAmsterdam Pharma has a 1 year low of $8.90 and a 1 year high of $26.35. The firm has a fifty day moving average price of $19.07 and a 200 day moving average price of $18.62.

NewAmsterdam Pharma Company Profile

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases.